Physician profile
Danielle Steffan
NPI 1568061794
$6,928.72
in general payments reported to CMS, 2019-2025
25 companies · $2,801 in 2025
The $2,801 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $867 · 2023: $1,970 · 2024: $1,291 · 2025: $2,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,654 · Education: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,654.15 |
| Education | $407.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,351.81 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $1,328.12 | 2022-2025 | |
| Janssen Biotech, INC. | $656.76 | 2022-2025 | Tremfya |
| Ucb, INC. | $537.67 | 2022-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $404.13 | 2022-2025 | Acthar |
| Lilly USA, LLC | $315.99 | 2022-2025 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $291.67 | 2022-2025 | Saphnelo |
| Pfizer INC. | $283.44 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $233.54 | 2023-2025 | Strensiq |
| Glaxosmithkline, LLC. | $216.82 | 2023-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $203.74 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $196.53 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $151.69 | 2025 | Yorvipath |
| E.R. Squibb & Sons, L.L.C. | $118.44 | 2023-2025 | Orencia |
| Radius Health, INC. | $118.41 | 2022-2025 | Tymlos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $116.44 | 2023-2025 | Idacio |
| Organon LLC | $72.82 | 2025 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $71.15 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $60.32 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $59.60 | 2023-2025 | |
| Invivyd INC | $50.14 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $37.54 | 2023 | Krystexxa |
| Nevro Corp. | $18.68 | 2024 | Senza |
| Sobi, INC | $18.34 | 2025 | |
| Celltrion USA INC. | $14.93 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Steffan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.